Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice : a retrospective cross-sectional analysis
Capdevila Castillón, Jaume (Hospital Universitari Vall d'Hebron)
Sevilla, Isabel (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia))
Alonso-Orduña, Vícente (Hospital Universitario Miguel Servet (Saragossa))
Antón Aparicio, Luís (Complejo Hospitalario Universitario de A Coruña)
Jiménez Fonseca, Paula (Hospital Universitario Central de Asturias)
Grande, Enrique (Hospital Universitario Ramón y Cajal (Madrid))
Reina, Juan-José (Hospital Universitario Virgen Macarena (Sevilla, Andalusia))
Manzano, José Luís (Hospital Universitari Vall d'Hebron)
Alonso Lájara, Juan Domingo (Hospital Universitario Virgen de la Arrixaca (Múrcia))
Barriuso, Jorge (Hospital Universitario La Paz (Madrid))
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid))
Medina, Javier (Complejo Hospitalario de Toledo)
López, Carlos (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Segura, Ángel (Hospital Universitari i Politècnic La Fe (València))
Carrera, Sergio (Hospital Universitario de Cruces (Barakaldo, País Basc))
Crespo, Guillermo (Hospital Universitario de Burgos)
Fuster, Josep (Hospital Universitari Son Dureta (Palma de Mallorca, Balears))
Munarriz, Javier (Consorci Hospitalari Provincial de Castelló)
García Alfonso, Pilar (Hospital General Universitario Gregorio Marañón)
Universitat Autònoma de Barcelona

Fecha:	2015
Resumen:	Based on the mechanism of action, combining somatostatin analogues (SSAs) with mTOR inhibitors or antiangiogenic agents may provide synergistic effects for the treatment of patients with neuroendocrine tumours (NETs). Herein, we investigate the use of these treatment combinations in clinical practice. This retrospective cross-sectional analysis of patients with NETs treated with the SSA lanreotide and targeted therapies at 35 Spanish hospitals evaluated the efficacy and safety of lanreotide treatment combinations in clinical practice. The data of 159 treatment combinations with lanreotide in 133 patients was retrospectively collected. Of the 133 patients, with a median age of 59. 4 (16-83) years, 70 (52. 6 %) patients were male, 64 (48. 1 %) had pancreatic NET, 23 (17. 3 %) had ECOG PS ≥2, 41 (30. 8 %) had functioning tumours, 63 (47. 7 %) underwent surgery of the primary tumour, 45 (33. 8 %) had received prior chemotherapy, and 115 (86. 5 %) had received prior SSAs. 115 patients received 1 lanreotide treatment combination and 18 patients received between 2 and 5 combinations. Lanreotide was mainly administered in combination with everolimus (73 combinations) or sunitinib (61 combinations). The probability of being progression-free was 78. 5 % (6 months), 68. 6 % (12 months) and 57. 0 % (18 months) for patients who only received everolimus plus lanreotide (n = 57) and 89. 3 % (6 months), 73. 0 % (12 months), and 67. 4 % (18 months) for patients who only received sunitinib and lanreotide (n = 50). In patients who only received everolimus plus lanreotide the median time-to-progression from the initiation of lanreotide combination treatment was 25. 8 months (95 % CI, 11. 3, 40. 3) and it had not yet been reached among the subgroup of patients only receiving sunitinib plus lanreotide. The safety profile of the combination treatment was comparable to that of the targeted agent alone. The combination of lanreotide and targeted therapies, mainly everolimus and sunitinib, is widely used in clinical practice without unexpected toxicities and suggests efficacy that should be explored in randomized prospective clinical trials.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Lanreotide ; Neuroendocrine tumours ; Sunitinib ; Everolimus ; Somatostatin analogues ; Clinical practice ; Cross-sectional analysis ; Combination treatment
Publicado en:	BMC Cancer, Vol. 15 (july 2015) , ISSN 1471-2407

DOI: 10.1186/s12885-015-1512-6
PMID: 26138480

11 p, 912.9 KB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados